BR0315596A - Substituted tetralines and indans - Google Patents

Substituted tetralines and indans

Info

Publication number
BR0315596A
BR0315596A BR0315596-0A BR0315596A BR0315596A BR 0315596 A BR0315596 A BR 0315596A BR 0315596 A BR0315596 A BR 0315596A BR 0315596 A BR0315596 A BR 0315596A
Authority
BR
Brazil
Prior art keywords
indans
substituted tetralines
tetralines
substituted
tetralins
Prior art date
Application number
BR0315596-0A
Other languages
Portuguese (pt)
Inventor
Xiaoli Chen
Keith T Demarest
Jung Lee
Jay M Matthews
Philip Rybczynski
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR0315596A publication Critical patent/BR0315596A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43—Y being a hetero atom
    • C07C323/44—X or Y being nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"TETRALINAS E INDANOS SUBSTITUìDOS". A invenção refere-se a compostos de tetralina e indano, composições contendo-os e métodos de uso dos mesmos como moduladores de PPAR alfa para tratar ou inibir a progressão de, por exemplo, dislipidemia."REPLACED TETRALINS AND INDANS". The invention relates to tetraline and indane compounds, compositions containing them and methods of using them as PPAR alpha modulators to treat or inhibit the progression of, for example, dyslipidemia.

BR0315596-0A 2002-10-21 2003-10-17 Substituted tetralines and indans BR0315596A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41993502P 2002-10-21 2002-10-21
US49527003P 2003-08-15 2003-08-15
PCT/US2003/033090 WO2004037778A1 (en) 2002-10-21 2003-10-17 Substituted tetralins and indanes

Publications (1)

Publication Number Publication Date
BR0315596A true BR0315596A (en) 2005-09-06

Family

ID=32179771

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315596-0A BR0315596A (en) 2002-10-21 2003-10-17 Substituted tetralines and indans

Country Status (17)

Country Link
EP (1) EP1569897A1 (en)
JP (1) JP2006503916A (en)
KR (1) KR20050055773A (en)
AU (1) AU2003277441B2 (en)
BR (1) BR0315596A (en)
CA (1) CA2502661A1 (en)
CR (1) CR7795A (en)
EA (1) EA009553B1 (en)
EG (1) EG24842A (en)
HR (1) HRP20050335A2 (en)
MX (1) MXPA05004191A (en)
NO (1) NO20052199L (en)
NZ (1) NZ539510A (en)
PL (1) PL376325A1 (en)
RS (1) RS20050318A (en)
TW (1) TW200418773A (en)
WO (1) WO2004037778A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1556344A1 (en) * 2002-10-21 2005-07-27 Janssen Pharmaceutica N.V. Treating syndrome x with substituted tetralins and indanes
ATE430728T1 (en) * 2002-10-21 2009-05-15 Janssen Pharmaceutica Nv SUBSTITUTED TETRALINES AND INDANES AND THEIR USE
AR048931A1 (en) 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv PROCESS FOR THE PREPARATION OF SUBSTITUTED AND INDIAN TETRALIN DERIVATIVES AND PREPARATION OF SYNTHESIS INTERMEDIARIES
AU2005302669A1 (en) * 2004-10-27 2006-05-11 Neurogen Corporation Diaryl ureas as CB1 antagonists
WO2007071766A2 (en) 2005-12-22 2007-06-28 Transtech Pharma Phenoxy acetic acids as ppar delta activators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
CA2400021A1 (en) * 2000-02-18 2001-08-23 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
WO2002028821A2 (en) * 2000-10-05 2002-04-11 Bayer Aktiengesellschaft Propionic acid derivatives with ppar-alpha activating properties
AU2002222549A1 (en) * 2000-11-29 2002-06-11 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
WO2002046146A1 (en) * 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Substituted carboxylic acid derivatives
JP2004517100A (en) * 2000-12-20 2004-06-10 グラクソ　グループ　リミテッド Substituted oxazoles and thiazoles as hPPARalpha agonists
WO2002064130A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Proliferative activator receptor (ppar) compounds
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
EP1556344A1 (en) * 2002-10-21 2005-07-27 Janssen Pharmaceutica N.V. Treating syndrome x with substituted tetralins and indanes
ATE430728T1 (en) * 2002-10-21 2009-05-15 Janssen Pharmaceutica Nv SUBSTITUTED TETRALINES AND INDANES AND THEIR USE

Also Published As

Publication number Publication date
KR20050055773A (en) 2005-06-13
EA009553B1 (en) 2008-02-28
HRP20050335A2 (en) 2006-05-31
CA2502661A1 (en) 2004-05-06
EG24842A (en) 2010-10-13
MXPA05004191A (en) 2006-01-27
JP2006503916A (en) 2006-02-02
NZ539510A (en) 2008-01-31
TW200418773A (en) 2004-10-01
CR7795A (en) 2012-10-25
AU2003277441A1 (en) 2004-05-13
EP1569897A1 (en) 2005-09-07
NO20052199L (en) 2005-06-24
RS20050318A (en) 2007-09-21
WO2004037778A1 (en) 2004-05-06
PL376325A1 (en) 2005-12-27
EA200500515A1 (en) 2005-10-27
AU2003277441B2 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
PT1237553E (en) COMBINATION OF AN INHIBITOR OF RECAPTACAO OF SEROTONIN AND AN ANTAGONISTA, OF AN INVESTMENT AGONIST OR OF A PARTIAL AGONIST FOR 5-HT2C
UY24949A1 (en) CALCILITE COMPOUNDS
BR0315566A (en) Substituted tetralines and indans
CY1110326T1 (en) SUBSTITUTED TETRALINS AND INDIA AND THEIR USE
BR9900320A (en) Antimicrobial composition
ECSP066434A (en) ACIDS 4 - ((PHENOXIALQUIL) UNCLE) -PHENOXYACETICS AND ANALOGS
CR7868A (en) COMBINATION FOR THE TREATMENT OF THE DISORDER FOR DEFICIT OF CARE WITH HYPERACTIVITY
PT1328269E (en) ASSOCIATE OF AN ANTAGONIST OF THE CB1 RECEPTOR AND SIBUTRAMINE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES FOR THE TREATMENT OF OBESITY
UY26130A1 (en) COMPOUNDS TO TREAT OBESITY
ES2165441T3 (en) INHIBITORS OF CALPAIN AND / OR CATEPSIN B OXAZOLIDIN REPLACED.
BRPI0414634A (en) b2 receptor agonists, amino substituted ethylamino adrenergic
BRPI0511099A (en) compounds and compositions as modulators of ppar
ES2058306T3 (en) SUBSTITUTED TETRALINS, CHROMANES AND RELATED COMPOUNDS IN THE TREATMENT OF ASTHMA, ARTHRITIS AND RELATED DISEASES.
BR0309278A (en) Compound, composition, methods for modulating ksp kinesin activity, for inhibiting ksp, for the treatment of a cell proliferative disease, and use of a compound
ECSP077319A (en) ACIDS 4 - ((PHENOXIALQUIL) UNCLE) -PHENOXYACETICS, AND ANALOGS OF THE SAME
PA8452701A1 (en) PROSTAGLANDIN AGONISTS
ECSP066435A (en) ACIDS 4 - ((PHENOXIALQUIL) UNCLE) -PHENOXYACETICS AND ANALOGS
ECSP077320A (en) ACIDS 4 - ((PHENOXIALQUIL) UNCLE) -PHENOXYACETICS AND ANALOGS
CL2007002387A1 (en) Use of compounds derived from 2,5-dihydroxybenzene for the treatment of arthritis and pain.
BR0315596A (en) Substituted tetralines and indans
CR20130055A (en) APPROPRIATE AROMATIC COMPOUNDS TO TREAT DISORDERS THAT RESPOND TO THE MODULATION OF DOPAMINE D3 RECEIVER
AR047553A1 (en) THE COMBINATION OF A SEROTONINE AND AGOMELATINE REABSORTION INHIBITOR
ECSP003458A (en) COMPOUNDS TO TREAT OBESITY

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JOHNSON AND JOHNSON (US)

Free format text: TRANSFERIDO DE: JANSSEN PHARMACEUTICA N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Application fees: publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.